NR3C1 and plasma cell myeloma: KS18 efficiently reduces Mcl-1 levels, whereas bortezomib obstructs proteasome function, and dexamethasone alters glucocorticoid receptor signaling, thus enhancing apoptotic stress on myeloma cells.